NCT05693116 Survival and Prognostic Factors of Squamous Cell Carcinoma of the Nasal Vestibule
| NCT ID | NCT05693116 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Istituto Clinico Humanitas |
| Condition | Nasal Vestibule Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2022-12-01 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2022-12-01 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn about survival and prognostic factors in patients who underwent surgical treatment for primary squamous cell carcinoma of the nasal vestibule. The main questions it aims to answer are: * what is the prognosis of patients affected by squamous cell carcinoma of the nasal vestibule? * are there any specific factors that could influence prognosis? * is it possible to elaborate a new staging system, able to overcome the limitations of the currently used ones? Data about patients, tumour and type of surgery performed will be collected. Participants will be followed-up for a minimum 6 months period after surgery.
Eligibility Criteria
Inclusion Criteria: * diagnosis of squamous cell carcinoma of the nasal vestibule * underwent upfront surgical treatment with curative intent * availability of clinical and radiological data for cT reassessment * availability of histological samples for pT reassessment * follow-up of at least 6 months after surgery. Exclusion Criteria: * patients initially referred for disease persistence or recurrence * patients affected by tumour involving the nasal vestibule but originating from other sites (eg. nasal cavities, skin of the nasal pyramid or upper lip)
Contact & Investigator
Fabio Ferreli, MD
PRINCIPAL INVESTIGATOR
Humanitas Research Hospital IRCCS, Rozzano-Milan
Frequently Asked Questions
Who can join the NCT05693116 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nasal Vestibule Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05693116 currently recruiting?
Yes, NCT05693116 is actively recruiting participants. Contact the research team at francesca.pirola@humanitas.it for enrollment information.
Where is the NCT05693116 trial being conducted?
This trial is being conducted at Toulouse, France, Rozzano, Italy, Cagliari, Italy, Milan, Italy and 2 additional locations.
Who is sponsoring the NCT05693116 clinical trial?
NCT05693116 is sponsored by Istituto Clinico Humanitas. The principal investigator is Fabio Ferreli, MD at Humanitas Research Hospital IRCCS, Rozzano-Milan. The trial plans to enroll 300 participants.